Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
RETATRUTIDE Completed phase 2 clinical studies in 2023 Currently in phase 3 clinical studies (expected to conclude 2026) FDA-approval anticipated 2027 Retatrutide is an experimental drug for obesity
In patients with NAFLD, hepatic FABP1, FABP4, and FABP5 mRNA levels were increased compared to non-NAFLD controls and FABP4 and 5 correlated with the percentage of liver fat [19, 35]
A maintenance dose is typically 25 to 50% of the therapeutic dose
The 30mg formulation supports higher-throughput protocols, extended study timelines, and experimental programs requiring larger material quantities across multiple assay runs, while the GLP-RT10mgformat provides a smaller-scale option for targeted receptor binding studies or early-stage pathway investigations
US$ 20.44
US$ 28.83
US$ 20.71
US$ 22.45
US$ 21.46
US$ 27.96
